AU2016226151B2 - Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent - Google Patents

Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent Download PDF

Info

Publication number
AU2016226151B2
AU2016226151B2 AU2016226151A AU2016226151A AU2016226151B2 AU 2016226151 B2 AU2016226151 B2 AU 2016226151B2 AU 2016226151 A AU2016226151 A AU 2016226151A AU 2016226151 A AU2016226151 A AU 2016226151A AU 2016226151 B2 AU2016226151 B2 AU 2016226151B2
Authority
AU
Australia
Prior art keywords
alternatively
cochleate
pharmacologically active
active agent
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016226151A
Other languages
English (en)
Other versions
AU2016226151A1 (en
Inventor
Ruying Lu
Raphael J. Mannino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Nanotechnologies Inc
Original Assignee
Matinas Biopharma Nanotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Nanotechnologies Inc filed Critical Matinas Biopharma Nanotechnologies Inc
Publication of AU2016226151A1 publication Critical patent/AU2016226151A1/en
Application granted granted Critical
Publication of AU2016226151B2 publication Critical patent/AU2016226151B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
AU2016226151A 2015-03-03 2016-03-03 Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent Active AU2016226151B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562127799P 2015-03-03 2015-03-03
US62/127,799 2015-03-03
US201562162425P 2015-05-15 2015-05-15
US62/162,425 2015-05-15
US201562163212P 2015-05-18 2015-05-18
US62/163,212 2015-05-18
US201562239675P 2015-10-09 2015-10-09
US62/239,675 2015-10-09
US201562247641P 2015-10-28 2015-10-28
US62/247,641 2015-10-28
US201562264164P 2015-12-07 2015-12-07
US62/264,164 2015-12-07
PCT/US2016/020722 WO2016141203A1 (en) 2015-03-03 2016-03-03 Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

Publications (2)

Publication Number Publication Date
AU2016226151A1 AU2016226151A1 (en) 2017-09-21
AU2016226151B2 true AU2016226151B2 (en) 2021-02-25

Family

ID=56848705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016226151A Active AU2016226151B2 (en) 2015-03-03 2016-03-03 Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

Country Status (8)

Country Link
US (1) US11389407B2 (enExample)
EP (1) EP3265060B1 (enExample)
JP (1) JP6770524B2 (enExample)
KR (1) KR20180004104A (enExample)
CN (1) CN107847443A (enExample)
AU (1) AU2016226151B2 (enExample)
CA (1) CA2978308C (enExample)
WO (1) WO2016141203A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200060424A (ko) * 2017-09-20 2020-05-29 아토픽 메디컬, 엘엘씨. 호흡기 질환 및 점막 염증의 치료 및 개선을 위한 조성물 및 방법
CN107621514B (zh) * 2017-11-10 2020-09-29 成都美域高制药有限公司 高效液相色谱法测定磷酸特地唑胺对映异构体含量的方法
KR101989789B1 (ko) * 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
WO2019199238A1 (en) * 2018-04-09 2019-10-17 Vet Products Research And Innovation Center Company Limited Inorganic mineral entrapped in nanoparticle production method thereof
WO2021030553A1 (en) * 2019-08-13 2021-02-18 Matinas Biopharma Nanotechnologies, Inc. Methods of treating cryptococcus infections
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
WO1995009648A1 (en) * 1993-10-04 1995-04-13 Gould Fogerite Susan Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US20050008686A1 (en) * 2003-01-15 2005-01-13 Mannino Raphael J. Cochleate preparations of fragile nutrients
US20120178793A1 (en) * 2004-04-09 2012-07-12 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
WO2014022414A1 (en) * 2012-07-30 2014-02-06 Coordinated Program Development, Llc Cochleates made with soy phosphatidylserine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CN1674869A (zh) * 2002-08-06 2005-09-28 金拓 非金属阳离子作桥联剂的脂质卷
EP1631669A2 (en) * 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
EP2704688B1 (en) 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same
WO2013085152A1 (en) * 2011-12-07 2013-06-13 Union Korea Pharm Co., Ltd. Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors
ES2867152T3 (es) 2015-04-22 2021-10-20 Matinas Biopharma Nanotechnologies Inc Composiciones y métodos para el tratamiento de infecciones y enfermedad pulmonar por micobacterias
JP2018517736A (ja) 2015-06-18 2018-07-05 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド 炎症性疾患又は病態を治療する組成物及び方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
WO1995009648A1 (en) * 1993-10-04 1995-04-13 Gould Fogerite Susan Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US20050008686A1 (en) * 2003-01-15 2005-01-13 Mannino Raphael J. Cochleate preparations of fragile nutrients
US20120178793A1 (en) * 2004-04-09 2012-07-12 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
WO2014022414A1 (en) * 2012-07-30 2014-02-06 Coordinated Program Development, Llc Cochleates made with soy phosphatidylserine

Also Published As

Publication number Publication date
CA2978308C (en) 2024-02-13
KR20180004104A (ko) 2018-01-10
EP3265060B1 (en) 2020-10-21
EP3265060A1 (en) 2018-01-10
US20180042849A1 (en) 2018-02-15
CN107847443A (zh) 2018-03-27
CA2978308A1 (en) 2016-09-09
JP2018508523A (ja) 2018-03-29
WO2016141203A1 (en) 2016-09-09
US11389407B2 (en) 2022-07-19
JP6770524B2 (ja) 2020-10-14
EP3265060A4 (en) 2018-08-22
AU2016226151A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
CA2978308C (en) Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
EP3285874B1 (en) Compositions and methods for treating mycobacteria infections and lung disease
US11648211B2 (en) Nanoencapsulated combination drug formulations
US20230372377A1 (en) Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa
US20240099979A1 (en) Enhanced two-stage microparticle-based localized therapeutic delivery system
JP2022103299A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2025026896A (ja) リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用
US20180185308A1 (en) Compositions and methods for treating inflammatory disease or conditions
CN115175664A (zh) 包含ati受体阻滞剂的脂质体制剂及其用途
JP2009292801A (ja) 経口用ナノ脂肪球製剤
CN115837016B (zh) 一种aoa-2-pxb@lnp脂质纳米粒及制备方法
CN114746084A (zh) 用于中耳炎的脂质涂层氧化铁纳米颗粒
WO2025212563A1 (en) Injectable hydrogel based on liposome self-assembly for sustained release of small hydrophilic molecules
HK40009841A (en) Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)